JP2024500335A - 抗ｃｄ３結合ドメインのためのペプチド組成物および方法 - Google Patents

抗ｃｄ３結合ドメインのためのペプチド組成物および方法 Download PDF

Info

Publication number
JP2024500335A
JP2024500335A JP2023534635A JP2023534635A JP2024500335A JP 2024500335 A JP2024500335 A JP 2024500335A JP 2023534635 A JP2023534635 A JP 2023534635A JP 2023534635 A JP2023534635 A JP 2023534635A JP 2024500335 A JP2024500335 A JP 2024500335A
Authority
JP
Japan
Prior art keywords
polypeptide
complex
seq
peptide
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500335A5 (https=
Inventor
キャンベル，デイビッド
アール． ディライモンド，トーマス
Original Assignee
ジャナックス セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャナックス セラピューティクス，インク． filed Critical ジャナックス セラピューティクス，インク．
Publication of JP2024500335A publication Critical patent/JP2024500335A/ja
Publication of JP2024500335A5 publication Critical patent/JP2024500335A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023534635A 2020-12-08 2021-12-07 抗ｃｄ３結合ドメインのためのペプチド組成物および方法 Pending JP2024500335A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122820P 2020-12-08 2020-12-08
US63/122,820 2020-12-08
PCT/US2021/062233 WO2022125562A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains

Publications (2)

Publication Number Publication Date
JP2024500335A true JP2024500335A (ja) 2024-01-09
JP2024500335A5 JP2024500335A5 (https=) 2024-12-12

Family

ID=81973732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534635A Pending JP2024500335A (ja) 2020-12-08 2021-12-07 抗ｃｄ３結合ドメインのためのペプチド組成物および方法

Country Status (9)

Country Link
US (1) US20240043536A1 (https=)
EP (1) EP4259177A4 (https=)
JP (1) JP2024500335A (https=)
KR (1) KR20230137301A (https=)
CN (1) CN116981682A (https=)
AU (1) AU2021396507A1 (https=)
CA (1) CA3201401A1 (https=)
MX (1) MX2023006733A (https=)
WO (1) WO2022125562A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013382A (es) 2020-04-04 2024-01-30 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4615514A2 (en) * 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3322715B1 (en) * 2015-07-14 2023-10-18 BioNTech SE Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
MX2023013382A (es) * 2020-04-04 2024-01-30 Janux Therapeutics Inc Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras.
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
EP4259202A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. COMPOSITIONS AND METHODS RELATED TO TUMOR-ACTIVATED ANTIBODIES AGAINST TROP2 AND EFFECTOR CELL ANTIGENS
AU2021396172A1 (en) * 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens

Also Published As

Publication number Publication date
MX2023006733A (es) 2023-08-14
CA3201401A1 (en) 2022-06-16
CN116981682A (zh) 2023-10-31
AU2021396507A1 (en) 2023-07-06
EP4259177A4 (en) 2024-11-06
US20240043536A1 (en) 2024-02-08
EP4259177A1 (en) 2023-10-18
WO2022125562A1 (en) 2022-06-16
KR20230137301A (ko) 2023-10-04

Similar Documents

Publication Publication Date Title
JP7681681B2 (ja) 切断可能リンカー組成物および方法
JP2024500335A (ja) 抗ｃｄ３結合ドメインのためのペプチド組成物および方法
TWI900703B (zh) 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
US12161724B2 (en) Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
JP2023552462A (ja) 半減期延長組成物および方法
US20250250339A1 (en) Antibodies targeting egfr and cd3 and uses thereof
US20240043565A1 (en) Antibodies targeting psma and cd3 and uses thereof
HK40102719A (zh) 用於抗-cd3结合结构域的肽组合物和方法
US12617865B2 (en) Activated antibodies targeting PSMA and effector cell antigens
WO2026096559A1 (en) Antibodies for targeting psma and uses thereof
WO2025097024A1 (en) Antibodies for targeting cd28 and uses thereof
CN117042792A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40101255A (zh) 涉及靶向psma和效应细胞抗原的肿瘤活化抗体的组合物和方法
HK40101216A (zh) 半衰期延长组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260119

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260127

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318